These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38148731)

  • 1. Optimizing the doses of cancer drugs after usual dose finding.
    Strohbehn GW; Stadler WM; Boonstra PS; Ratain MJ
    Clin Trials; 2024 Jun; 21(3):340-349. PubMed ID: 38148731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.
    Lee SM; Backenroth D; Cheung YK; Hershman DL; Vulih D; Anderson B; Ivy P; Minasian L
    J Clin Oncol; 2016 Apr; 34(12):1395-401. PubMed ID: 26926682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next generation oncology drug development: opportunities and challenges.
    Gutierrez ME; Kummar S; Giaccone G
    Nat Rev Clin Oncol; 2009 May; 6(5):259-65. PubMed ID: 19390552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of the partial-order continual reassessment method in the early development of treatment combinations.
    Wages NA; Dillon PM; Portell CA; Slingluff CL; Petroni GR
    Clin Trials; 2024 Jun; 21(3):331-339. PubMed ID: 38554038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose optimization for cancer treatments with considerations for late-onset toxicities.
    Biard L; Andrillon A; Silva RB; Lee SM
    Clin Trials; 2024 Jun; 21(3):322-330. PubMed ID: 38591582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The patient perspective on dose optimization for anticancer treatments: A new era of cancer drug dosing-Challenging the "more is better" dogma.
    Maués J; Loeser A; Cowden J; Johnson S; Carlson M; Lee S
    Clin Trials; 2024 Jun; 21(3):358-362. PubMed ID: 38385314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical and practical considerations in planning and conduct of dose-optimization trials.
    Yuan Y; Zhou H; Liu S
    Clin Trials; 2024 Jun; 21(3):273-286. PubMed ID: 38243399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
    Tighiouart M; Li Q; Rogatko A
    Stat Med; 2017 Jan; 36(2):280-290. PubMed ID: 27060889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the Therapeutic Window of Targeted Drugs in Oncology: Potency-Guided First-in-Human Studies.
    Goldstein MJ; Peters M; Weber BL; Davis CB
    Clin Transl Sci; 2021 Mar; 14(2):536-543. PubMed ID: 33048459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus.
    Thall PF; Garrett-Mayer E; Wages NA; Halabi S; Cheung YK
    Clin Trials; 2024 Jun; 21(3):267-272. PubMed ID: 38570906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DROID: dose-ranging approach to optimizing dose in oncology drug development.
    Guo B; Yuan Y
    Biometrics; 2023 Dec; 79(4):2907-2919. PubMed ID: 36807110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle.
    Jänne PA; Kim G; Shaw AT; Sridhara R; Pazdur R; McKee AE
    Clin Cancer Res; 2016 Jun; 22(11):2613-7. PubMed ID: 27250931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.
    Wages NA; Tait C
    J Biopharm Stat; 2015; 25(5):903-20. PubMed ID: 24904956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving early phase oncology clinical trial design: The case for finding the optimal biological dose.
    Phillips A; Mondal S
    Pharm Stat; 2023; 22(4):739-747. PubMed ID: 36669771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose finding with continuous outcome in phase I oncology trials.
    Wang Y; Ivanova A
    Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finding the right dose for cancer therapeutics--can we do better?
    Rubin EH; Anderson KM
    Clin Cancer Res; 2010 Feb; 16(4):1085-7. PubMed ID: 20145182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Introduction of Oncology Dose-Finding Trial Designs].
    Takeda K
    Gan To Kagaku Ryoho; 2022 Apr; 49(4):365-370. PubMed ID: 35444116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
    Tighiouart M; Cook-Wiens G; Rogatko A
    J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying the most successful dose (MSD) in dose-finding studies in cancer.
    Zohar S; O'Quigley J
    Pharm Stat; 2006; 5(3):187-99. PubMed ID: 17080752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.